|Bid||19.25 x 900|
|Ask||19.30 x 900|
|Day's Range||18.80 - 19.40|
|52 Week Range||8.60 - 19.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 27, 2017 - Jul 28, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.50|
Short interest is high for ALDR with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting ALDR. The net inflows of $2.00 billion over the last one-month into ETFs that hold ALDR are not among the highest of the last year and have been slowing.
Investors in Alder Biopharmaceuticals (ALDR) need to pay close attention to the stock based on moves in the options market lately.
-Data presented today at the American Headache Society Annual Scientific Meeting demonstrate eptinezumab’ s robust efficacy is further improved at one year following third and fourth quarterly infusions. ...
-Data presented today at the American Headache Society Annual Scientific Meeting demonstrate 43% of patients receiving 300 mg of eptinezumab achieved a 75% or greater reduction of monthly migraine days. ...
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Newfield ...
Short interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. Over the last month, growth of ETFs holding ALDR is favorable, with net inflows of $5.46 billion.
BOTHELL, Wash., June 20, 2018-- Alder BioPharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will ...
Alder Biopharmaceuticals gapped up Friday after rival Teva Pharmaceutical scrapped a late-stage study in chronic cluster headaches.
Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported the grant of inducement awards to Robert (“Bob”) Azelby, effective as of June 13, 2018. The compensation committee of Alder's board of directors granted Mr. Azelby (a) an option to purchase 1,000,000 shares of common stock (the “Time-Based Option”) and (b) an option to purchase 150,000 shares of common stock (the “Performance-Based Option”), each pursuant to Alder’s 2018 Inducement Award Plan. The Time-Based Option will vest with respect to 25% of the shares underlying the Time-Based Option one year after Mr. Azelby’s employment start date and the remaining 75% of the shares underlying the Time-Based Option will vest in equal monthly installments over the 36 month period following the one year anniversary of Mr. Azelby’s employment start date, subject to his continued service to Alder through each relevant vesting date.
The hire could fuel rumors that Alder is searching for a buyer at the same time the Bothell-based company is seeking Food and Drug Administration approval for its flagship migraine drug, eptinezumab.
LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on ALDR sign up now at www.wallstequities.com/registration. Gains were broad based as seven out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and Altimmune Inc. (NASDAQ: ALT).
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
Alder Biopharmaceuticals likely will seek a buyer, an analyst said Thursday as shares tanked on the hire of a new chief executive.
Alder BioPharmaceuticals, Inc. (ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today named biotech industry veteran Robert W. Azelby president and chief executive officer of Alder, effective June 13, 2018. Mr. Azelby joins Alder from Juno Therapeutics, Inc., where he served as executive vice president and chief commercial officer. Mr. Azelby was a member of Juno’s executive management team and helped guide the organization through rapid growth and ultimately, to a $9 billion acquisition by Celgene Corporation.
On May 23, Teva Pharmaceutical Industries (TEVA) announced that the FDA has confirmed the PDUFA date for its migraine drug Fremanezumab as September 16, 2018, against the previously provided date of June 16. The approval was delayed due to an FDA warning received by Teva’s partner Celltrion in February. Guggenheim analyst Rohit Vanjani believes the FDA approval delay could prove to be positive ultimately if the re-inspection at the Celltrion facility is completed without any further issues.
Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.
NEW YORK, May 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Armstrong ...
The Bothell, Washington-based company said it had a loss of $1.73 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
-12- Month Data Presented at American Academy of Neurology Annual Meeting Demonstrated Eptinezumab Further Reduced Migraine Risk Following Third and Fourth Quarterly Infusions-. -Biologics License Application ...
Alder Biopharmaceuticals Inc’s (NASDAQ:ALDR): Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The US$899.01M market-cap company announced a latest loss of -US$288.88M on 31 December 2017 for its mostRead More...
BOTHELL, Wash., May 07, 2018-- Alder BioPharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will ...